HCWB Stock Analysis: Buy, Sell, or Hold?
HCWB - HCW Biologics Inc. Common Stock
$4.30
-0.28 (-6.11%)
▼
5d:
+283.93%
30d:
+140.22%
90d:
+1333.33%
WAIT
LOW Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 17, 2026
Get Alerted When HCWB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: HCWB is 49.3% above its trading range ($2.88). While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: HCWB is 49.3% above its trading range ($2.88). While momentum could continue, risk/reward favors waiting for a pullback.
In-depth Analysis How we analyze
Valuation Analysis: HCWB is currently trading at $4.30, which is considered extended relative to its 30-day fair value range of $0.72 to $2.88.
Technical Outlook: Technically, HCWB is in a downtrend. The price is approaching resistance at $2.67. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. Short-term momentum is weak, with the stock down 6.1% recently.
Market Sentiment: HCWB has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $30.00 (+597.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, HCWB is in a downtrend. The price is approaching resistance at $2.67. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. Short-term momentum is weak, with the stock down 6.1% recently.
Market Sentiment: HCWB has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $30.00 (+597.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$0.72 -
$2.88
Company Quality Score
48/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
47.4%
All Signals
- BEARISH: Price significantly overextended (+49.3% above its trading range)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-6.1%)
- BULLISH: Trading 597.7% below Wall St target ($30.00)
- WARNING: Recommendation downgraded due to 49.3% overvaluation
Trading Range Analysis
30-Day Trading Range
$0.72 -
$2.88
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$1.10
Resistance Level
$2.67
Current Trend
Downtrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.63
Wall Street Target
$30.00
(+597.7%)
Revenue Growth (YoY)
129080.7%
Profit Margin
-34.7%
Share & Embed Analysis
Last updated: July 02, 2026 9:39 PM ET
Data refreshes hourly during market hours. Next update: 10:39 PM
Data refreshes hourly during market hours. Next update: 10:39 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is HCWB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 63 BUY |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1041 | 62 BUY |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$84 | 63 BUY |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$106 | 64 BUY |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 61 BUY |
